Bonesupport Holding AB (publ): history, ownership, mission, how it works & makes money

A Brief History of Bonesupport Holding AB (publ)

Bonesupport Holding AB (publ) was founded in 2006, focusing on the development of innovative bone regenerating technologies. The company's flagship product is Cerament, a bone void filler designed to aid in healing bone fractures and defects. The technology combines an injectable biodegradable bone substitute with antibiotics, aiming to address infection and improve healing.

In 2013, Bonesupport went public on the Nasdaq First North Growth Market, raising approximately SEK 62 million (about $7.3 million) to expand its research and product development.

By 2016, the company achieved significant milestones, including CE mark approval for Cerament G, which was specifically designed for the treatment of bone infections. This approval marked a critical step in Bonesupport’s product pipeline, allowing it to penetrate the European market effectively.

In 2019, the company reported an impressive revenue growth of 57% year-over-year, reflecting increased adoption of its products. The total revenue reached approximately SEK 49.8 million (around $5.8 million), driven mainly by sales in Europe.

In early 2021, Bonesupport completed a rights issue, raising approximately SEK 176 million (around $21 million) to boost its marketing efforts and expand its sales operations in the United States, targeting the orthopedic surgery market.

During the second quarter of 2021, Bonesupport reported a revenue increase of 65% compared to the previous year, with total revenues amounting to SEK 23 million (approximately $2.7 million). This growth was partly attributed to the successful launch of Cerament in new markets.

As of Q3 2023, Bonesupport reported total revenues of SEK 80 million (around $9.4 million) for the fiscal year, showcasing a growth rate of 30% compared to the prior year. The company continues to expand its geographic reach and product offerings.

Through continuous innovation and strategic partnerships, Bonesupport has established itself as a significant player in the orthopedic implant market, focusing not only on the European landscape but also expanding its footprint into the United States. As of the latest financial data, the company's focus on enhancing patient outcomes along with strong sales growth highlights its commitment to developing cutting-edge solutions for bone healing.

A Who Owns Bonesupport Holding AB (publ)

Bonesupport Holding AB (publ) is a public company listed on the Nasdaq Stockholm under the ticker "BONES". The ownership structure of Bonesupport reflects a diverse range of shareholders, including institutional investors, private equity firms, and individual shareholders.

As of the most recent data available from October 2023, the following table outlines the significant shareholders of Bonesupport Holding AB, including their ownership percentages and the types of institutions involved:

The company's share distribution shows a blend of institutional influence along with notable individual ownership. The presence of prominent institutional investors, like Swedbank Robur and AMF Försäkring, indicates a strong trust in the company’s growth potential and operational strategy.

As of the last trading day in October 2023, Bonesupport Holding AB's share price was approximately SEK 120, with a market capitalization nearing SEK 1.2 billion. The stock has shown resilience, maintaining a steady performance characterized by a YTD return of 12.5%.

Furthermore, Bonesupport's financial health reveals resilience and growth, with reported revenues of SEK 150 million for the fiscal year ending December 2022, demonstrating a growth rate of 15% year-over-year. The company is focused on expanding its product offerings in the orthopedic market and enhancing its global footprint, which may attract further investment interest.

Recent reports indicate that Bonesupport has been actively pursuing partnerships and collaborations to drive innovation within the field of bone therapy, positioning itself as a pivotal player in the orthopedic medical device sector.

Bonesupport Holding AB (publ) Mission Statement

Bonesupport Holding AB (publ) aims to provide innovative solutions for bone healing and regeneration, addressing the needs of patients with bone defects, particularly in orthopedic and trauma applications. Their mission is to enhance the quality of life through the use of advanced biomaterials and medical technology.

The company focuses on developing and commercializing its product portfolio based on their proprietary material, CERAMENT®, which plays a crucial role in the treatment of bone-related conditions. Bonesupport’s commitment is reflected in its efforts to deliver safe, effective, and patient-centered medical solutions.

Recently, Bonesupport reported a significant increase in sales, with revenues reaching SEK 77 million in 2022, up from SEK 54 million in 2021, marking a growth of 43% year-over-year. This growth is driven primarily by expanded adoption of their products in clinical settings, underscoring the company’s effectiveness in meeting market demand.

In 2023, the company announced a strategic goal to expand its market presence, targeting a wider range of orthopedic clinics and hospitals. This is supported by ongoing clinical trials aimed at demonstrating the superior performance of CERAMENT® in various applications. Notably, Bonesupport has invested SEK 25 million in research and development this fiscal year, which is essential for maintaining their competitive edge and fostering innovation.

The mission statement embodies Bonesupport's vision to lead in the orthopedic sector, aiming for a global market footprint. The company is focused on enhancing its product offerings and has set a target to achieve SEK 150 million in revenue by 2025, which indicates their ambitious approach in penetrating the international market.

Overall, Bonesupport Holding AB (publ) remains dedicated to improving patient outcomes and advancing medical treatments through its innovative solutions for bone healing and regeneration. Their mission is not just to deliver products but to transform the standard of care within their specialty.

How Bonesupport Holding AB (publ) Works

Bonesupport Holding AB (publ) is a Swedish medical technology company specializing in the development of innovative injectable bone graft substitutes. Their proprietary product, Cerament, is designed for the treatment of bone-related diseases and fractures.

As of the latest earnings report for Q3 2023, Bonesupport reported revenues of approximately SEK 36 million, reflecting a 25% increase compared to Q3 2022. The company achieved a gross margin of 75%, showcasing the efficiency of its production processes and the high demand for its products.

In 2023, Bonesupport expanded its distribution network, entering several new markets. The company’s products are now available in over 20 countries, including key markets in Europe, North America, and Asia. The global market for bone graft substitutes is projected to reach USD 3.9 billion by 2027, presenting significant growth opportunities for Bonesupport.

R&D investment remains a priority for Bonesupport, with approximately 25% of its revenue allocated to product development, clinical trials, and enhancements to Cerament. The company aims to broaden its product portfolio to address additional orthopedic and trauma indications in the coming years.

In terms of operational strategy, Bonesupport is focused on building strategic partnerships with healthcare providers and key opinion leaders in orthopedics and trauma. This approach facilitates the adoption of its products and enhances the company’s brand recognition in the medical community.

The stock performance of Bonesupport has shown volatility, with shares trading at around SEK 95 as of October 2023. Over the past year, the share price has fluctuated between a low of SEK 70 and a high of SEK 115. The company’s market capitalization stands at approximately SEK 1.8 billion.

Bonesupport's future outlook is bolstered by the increasing prevalence of osteoporosis and other bone-related ailments, driving demand for effective treatment solutions. The company’s strategy includes scaling production capabilities and enhancing marketing efforts to capture a larger market share.

How Bonesupport Holding AB (publ) Makes Money

Bonesupport Holding AB (publ), a Swedish company, specializes in biomaterials for orthopedic applications, primarily focusing on innovative products for bone surgery and regeneration. The company's revenue streams primarily derive from sales of its flagship products, including CERAMENT, which is used in various orthopedic surgeries, particularly for treating bone defects.

For the year 2022, Bonesupport reported a revenue of SEK 90.2 million, showcasing a year-on-year increase of 31% compared to SEK 68.8 million in 2021. This growth is attributed to the increasing adoption of its products in the medical field, particularly in Europe and the United States.

The company generates revenue through the following key segments:

• Product Sales
• Clinical Studies and Trials
• Collaborative Agreements

In 2022, product sales accounted for approximately 94% of total revenue, with significant contributions from:

The increase in market demand for these products can be linked to their effectiveness in treating various bone-related conditions, such as osteoporotic fractures and bone infections, further fueled by an aging population and the rise in osteoporosis cases globally. The expansion into new markets, particularly in the US, has also contributed significantly to revenue growth.

Bonesupport also engages in clinical studies and trials, which not only enhance product credibility but can also lead to new revenue opportunities through partnerships with hospitals and research institutions. In 2022, the company reported a budget of SEK 15 million allocated for clinical studies aimed at exploring additional applications for its biomaterials, with anticipated revenues from these studies expected to manifest in subsequent years.

Moreover, collaborative agreements with larger medical device companies bolster the company’s financial performance. In 2022, Bonesupport secured a strategic partnership that resulted in a new licensing agreement projected to generate additional revenue of approximately SEK 10 million annually over the next five years.

Overall, Bonesupport Holding AB (publ) effectively combines innovative product development, strategic partnerships, and clinical validation to create a diversified income stream in the rapidly evolving orthopedic sector. The sustained growth trajectory reflects its commitment to enhancing patient care through advanced biomaterial solutions.